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Abstract
The microenvironment of a tumor is constituted of a heterogenous population of stromal cells, extracellular matrix
components, and secreted factors, all of whichmake the tumor microenvironment distinct from that of normal tissue.
Unlike healthy cells, tumor cells require these unique surroundings to metastasize, spread, and form a secondary
tumor at a distant site. In this review, we discuss that stromal cells such as fibroblasts and immune cells including
macrophages, their secreted factors, such as vascular endothelial growth factor, transforming growth factor β, and
various chemokines, and the integrins that connect the various cell types play a particularly vital role in the survival of a
growing tumor mass. Macrophages and fibroblasts are uniquely plastic cells because they are not only able to switch
from tumor suppressing to tumor supporting phenotypes but also able to adopt various tumor-supporting functions
based on their location within the microenvironment. Integrins serve as the backbone for all of these prometastatic
operations because their function as cell-cell and cell-matrix signal transducers are important for the heterogenous
components of the microenvironment to communicate.
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Introduction
With more than half a million people dying in the United States from
cancer each year, the prevention and treatment of cancer have come to
the forefront of biomedical research in the last three decades. Extensive
research on neoplasia has led to a profound understanding of how
normal cells acquire specific genetic mutations in their progression to
either benign or malignant cells. Through these genetic alterations,
cancer cells acquire the ability to survive and proliferate with minimal
adhesion to the extracellular matrix (ECM) and to evade antigrowth
signals and apoptosis. They also are able to multiply without limit and
sustain nutrients by angiogenesis. Although thesemutations characterize
all cancer cells, only malignant cells rather than benign ones are able to
invade the surrounding tissue and spread to other parts of the body by
metastasis. In order for the progression and metastasis of tumor cells
to occur, several obligatory steps must be completed. Cancer cells must
first separate from the primary tumor, degrade the physically barring
basement membrane and interstitial matrix of the ECM, and invade
the walls of the circulatory system in a process known as intravasation.
Because cancer cells must penetrate the basement membrane and breach
cell-cell adhesions, they often enter the circulatory system through blood
vessels or lymph vessels, both of which, in the cancerous condition, have
discontinuous basement membranes and irregular cell-cell junctions
[1,2]. The process of intravasation is crucial to the metastatic process
because tumors that are removed before these initial steps seldom recur
[3]. Once they have entered the circulatory system, cancer cells must be
transported through the body, a rigorous process wherein normal epi-
thelial cells do not survive. Immune recognition, anoikis (cell death
associated with detachment from the ECM), and the physical stress of
the circulatory system are all factors that the cancer cell must evade be-
fore it can come to rest at a distant organ. Finally, the cancer cell must
leave the bloodstream and gain access to the secondary site by inducing
angiogenesis and/or by appropriating existing blood vessels [4].
Nevertheless, genetic mutations alone are not sufficient to allow
cancer cells to fully undergo the complexmetastatic process. The tumor’s
microenvironments at the primary tumor, during circulation, and at
the secondary site are all pivotal to tumor metastasis and progression.
According to the Paget “seed and soil” hypothesis, “bad seed” (tumors)
will only develop in a “good soil” (environment) that supports tumor
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formation. Previously, it had been thought that cancer cells had the
potential to metastasize in any number of locations by releasing fac-
tors that modify surrounding normal cells into cancer cells. However,
the “seed and soil” hypothesis suggests that it is the mutual interaction
between the cancer cell and its specific microenvironment that contri-
butes to tumor formation [4]. Just as cancer cells affect the surround-
ing normal cells, the heterogeneous mixture of cells in the surrounding
environment will, in turn, promote progression of the tumor by stim-
ulating growth, survival, invasion, and metastasis. In addition, tumor
growth is dependent on the conditions of the tumor microenviron-
ment, such as low glucose, low pH, and low levels of oxygen, called
hypoxia [5]. However, at this point, very little is understood about
the mechanisms by which this interaction occurs. This review broadly
summarizes recent progress in the understanding of how different
cell types participate in the development of a microenvironment that
favors tumor cell invasion and metastasis. In this review, we will discuss
the important role of macrophages, fibroblasts, and integrins in the
tumor microenvironment.
Protumorogenic Activities of Stromal Cells
in the Microenvironment
Defining the Microenvironment
The microenvironment consists of an amalgam of secreted soluble
factors, noncellular solid material, and stromal cells that directly sur-
round the tumor cells. Secreted soluble factors include chemokines
such as CXCR-4 and CXCL-12,matrix-altering enzymes such as matrix
metalloproteinases (MMPs), protease inhibitors, and growth factors
such as vascular endothelial growth factor (VEGF), all of which are
stored in the surrounding ECM and released when required by the
tumor cells. The surrounding ECM itself, which is composed of the in-
terstitial matrix and basement membrane, constitutes the noncellular
solid material that is critical in the anchorage and migration of malig-
nant cancer cells. However, a central focus of this review will be on stro-
mal cells, particularly fibroblasts, endothelial cells, and macrophages,
(Figure 1), which are present in the surrounding environment but are
recruited by tumors to promote malignant progression, cell escape and
survival, and growth at the secondary site.
Macrophages
Macrophages are released by the bone marrow, after which they
navigate through the circulatory system before landing at tissues in
the bone, liver, or lung.Oncemature,macrophages then act as a cardinal
defense mechanism against wounding and/or infection. This includes
alerting the immune system to the presence of harmful tumor cells by
secreting chemokines that recruit other immune cells to the area and by
producing growth factors and angiogenic factors such as VEGF.
Whereas macrophages under normal conditions often exhibit anti-
tumorogenic properties, macrophages under cancerous conditions have
also been shown to be key participants in the prometastatic process by
enhancing tumor cell migration, invasion, and intravasation [6,7]. Fur-
thermore, they also promote angiogenesis and thereby promote greater
tumor size and grade [8]. Macrophages are able to possess both tumor-
suppressing and tumor-promoting properties because of their distinct
M1 and M2 phenotypes. These two phenotypes not only give macro-
phages a unique sense of plasticity but also allow the tumor to elicit dis-
tinct functions from thesemacrophages depending on the stage of tumor
progression [8]. “Classically activated” M1 macrophages contribute to
Figure 1. Summary of the microenvironment. The tumor mass microenvironment is composed of a heterogeneous mixture of stromal
cells (such as fibroblasts, endothelial cells, and immune cells such as macrophages) and ECM components. The tumor mass uses these
various cell types to secrete chemokines such as CXCR4/CXCL12, growth factors such as VEGF and TGF-β, and matrix-degrading proteins
(MMPs) to create a prometastatic niche that supports the tumor during invasion, angiogenesis, and extravasation. In addition, integrins and
their receptors mediate cellular attachment and communication.
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tumor rejection through type 1 cytokine production and antigen presen-
tation [9]. However, during tumor progression, a phenotypical switch
occurs: macrophages begin to express the “alternatively activated” M2
phenotype instead of the M1 phenotype. Expression of the M2
phenotype, consequently, leads to enhanced angiogenesis, matrix re-
modeling, and suppression of the immune system’s ability to alert other
immune cells to the presence of cancer cells [9]. Thus, the tumor micro-
environment causes inflammatory cells such as macrophages to become
cancer promoting rather than cancer suppressing.
Tumor-associated macrophages (TAMs), in particular, have been
shown to share the M2 phenotype [10]. TAMs are a large component
of the tumor microenvironment because they can comprise up to 80%
of the tumor mass in breast cancer [11]. Clinical studies have found a
correlation between high TAM content of tumors and poor patient
prognosis [12]. Joyce and Pollard suggest that the tumor microenviron-
ment contains several subpopulations of TAMs, each with various func-
tions based on the stage of tumor progression and on its geographical
location in the microenvironment. For instance, TAMs located in the
hypoxic region of the microenvironment support angiogenesis [13],
whereas TAMs at the intersection of tumor cells and stromal cells sup-
port both invasion and angiogenesis. In studies that depleted the mac-
rophage population through genetic manipulation or pharmacological
knockout, substantially fewer macrophages were found in the tumor
microenvironment, which correlated to a marked decrease in angio-
genesis, tumor growth, and metastasis [14].
Angiogenesis is essential in providing the metastatic tumor with the
blood, nutrients, and oxygen necessary for uninhibited proliferation
and sustainability. Without this private blood supply, tumors are only
be able to grow to a minimal volume of 1 to 2 mm3, a volume that
expands rapidly to 1 to 3 cm3 when vasularization occurs [15]. Angio-
genesis is supported by the large presence of TAMs in areas of low
oxygen concentration [13]. Hypoxia activates TAMs, causing them
to indirectly upregulate VEGF [16]. VEGF is a principal mediator
in angiogenesis and has been observed to be one of the most potent
angiogenic factors to have been discovered. In a cascade of events, hyp-
oxic conditions in the microenvironment cause TAMs to increase the
gene expression of hypoxia-inducing factor 1 (HIF-1). HIF-1, in turn,
upregulates VEGF [17]. Expression of VEGF results in increased
vascular permeability and digestion of the ECM so that a new blood
vessel can form and furnish the growing tumor with essential nutrients
and supplies. In rat carcinoma models, the level of microvessel density
positively correlated to the levels of both HIF-1 and VEGF [18] and to
the level of TAM density [19], suggesting that the presence of all three
factors in the microenvironment are important in tumor development
by promoting angiogenesis.
Fibroblasts
Along with macrophages, fibroblasts have recently garnered atten-
tion as having a greater influence on the development and progression
of tumors than was previously thought. Under normal circumstances,
fibroblasts help maintain the structural integrity of connective tissue by
synthesizing precursors for the ECM and the stroma for tissues. How-
ever, in the cancer microenvironment, fibroblasts have been shown to
secrete cell surface proteins and growth factors that prop the micro-
environment to be in a tumor-enhancing position. In particular, acti-
vated fibroblasts, or myofibroblasts, appear shortly before the invasive
stage of tumors and promote degradation of the ECM by secreting
serine proteases, MMPs, and urokinase plasminogen activator (uPA)
receptor (uPAR). By doing so, fibroblasts not only stimulate their own
migration into the tumor but also promote survival, proliferation, and
invasion of cancer cells, thereby enhancing metastasis [20].
Fibroblasts are particularly useful to the tumor mass in the hypoxic
conditions of the microenvironment. The supply of insufficient oxy-
gen levels to the tumor leads to an anaerobic condition of lactic acid
build-up [21]. The accumulation of this lactic acid establishes a micro-
environment that is not only hypoxic but also acidic. Only those cells
that can survive these highly acidic conditions can go on to join the
growing tumor cell mass. Koukourakis et al. [22] demonstrated that
in colorectal cancer specimens, fibroblasts are able to remove toxic
metabolites and buffer the acidity generated by cancer cells. Thus,
the presence of fibroblasts in the microenvironment allows more cells
to survive the low pH conditions and join the growing tumor mass,
thereby increasing the rate of tumor progression and metastasis. Fur-
thermore, fibroblasts located in tissues closer to the outside environment
of the body secrete interferon β (IFN-β) [23]. These interferons are part
of the larger family of cytokines, which defend the body against tumor
cells by activating natural killer cells, macrophages, and other inflam-
matory response cells. In fact, IFN-β secreted by some fibroblasts is
suggested to have an anticancer effect because mice that have reduced
IFN-β activity show increased tumor formation, progression, and inva-
siveness [24]. Thus, fibroblasts assume different phenotypes, whether
it is the protumorigenic phenotye of buffering acidity or the anti-
tumorigenic phenotype of recruiting immune cells based on the stimuli
generated by the microenvironment.
Several studies pinpointed activated fibroblasts, namely carcinoma-
associated fibroblasts (CAFs), as being indispensable to a microenvi-
ronment that promotes tumor growth and angiogenesis. First, CAFs
possess a larger concentration of α-smooth muscle actin, which are
characteristic of the myofibroblasts found in the stroma of invasive
breast cancers, and collagen elasticity, which contributes to an in-
creased rate of ECM permeability [25]. Second, breast cancer cell lines
that were coinjected with CAFs resulted in tumors that possessed 7.6-
fold greater vasculature and 4.7-fold greater blood microvessel density
than those tumors that were coinjected with normal stromal fibroblasts
[26]. This finding indicates that CAFs aid not only in tumor angio-
genesis but also in proliferation because those tumors that are better
vascularized are able to receive more nutrients essential to sustain
growth. Thirdly, CAFs retained their protumorigenic properties de-
spite losing contact with the breast carcinoma cells [26], indicating
that CAFs may be a critical part of the microenvironment that sustains
the tumor as it travels from the primary tumor to its distant secondary
site (Figure 2).
The transition of stromal fibroblasts from their normal state to
their activated CAF state may be induced by increased levels of
MMP-1 and the chemokine CXCR4 [27]. MMP-1 and CXCR4
were particularly chosen for study because they are found at increased
levels in breast cancer cells and primary breast tumors but not in
normal tissues [28,29]. Eck et al. found that SUM102 breast cancer
cells induced normal fibroblasts to attain CAF-like properties by
stimulating the expression of MMP-1 and CXCR4. The normal
fibroblasts with increased concentrations of MMP-1 and CXCR4
and therefore CAF-like properties demonstrated increased migratory
and invasive capabilities.
Thus, the presence of both macrophages and fibroblasts in the tumor
microenvironment is pivotal to the growing tumor mass. Without
these stromal cells in the microenvironment, tumors would be unable
to secrete the factors necessary to succeed in angiogenesis, ECM degra-
dation, invasion, and migration.
1266 Integrins and Tumor Microenvironment Alphonso and Alahari Neoplasia Vol. 11, No. 12, 2009
Epigenetic Alterations in Stromal Cells of
the Microenvironment
To understand the dual role of protumorigenic and antitumorigenic
macrophages and fibroblasts on a molecular level, Ma et al. [30] con-
ducted a comparative analysis of gene expression changes in normal
epithelia, normal stroma, tumor epithelia, and tumor-associated stroma
using laser capture microdissection and DNA microarrays. Their study
found that the genetic changes of the tumor-associated stroma were
similar to those of the tumor epithelium. In particular, they found that
tumor stroma that had reached the invasive stage expressed an increased
level ofMMPs, such asMMP-2. These findings support the theory that
the tumor mass and its microenvironment have reciprocal relationships
with both undergoing genetic expression alterations even in the pre-
invasive stage of cancer [31].
Whereas studies have found genetic abnormalities in tumor epithe-
lial cells [32], few studies to date have demonstrated genetic mutations
in stromal cells of the tumor microenvironment [33–35]. In an attempt
to explain why tumor-associated stromal cells maintain altered genetic
expression despite a lack of genetic mutation, Hu et al. [36] suggest that
tumor-associated stromal cells maintain their protumorigenic pheno-
types because of epigenetic modifications, such as DNA methylation.
DNA methylation changes between normal and neoplastic cells have
been found in breast cancer [36], lung cancer [37], and prostate cancer
[38]. For example, lung and breast cancer cells were found to have lost
expression of RRAD, a Rad-related GTPase, whereas the expression of
RRAD in normal lung and breast cancer cells remained unaffected.
However, the expression of RRAD was restored when either the breast
or the lung cancer cells were treated with the demethylating agent 5-Aza-
2′-deoxycytidine [37]. Recent discoveries have foundmore than 50 bio-
markers of breast cancer that are based on DNA methylation. These
biomarkers have been accurate in detecting DNA hypermethylation
inmore than 90% of breast cancer cases, suggesting possible therapeutic
routes during tumor development [39].
Protumorogenic Activities of Integrins in
the Microenvironment
In addition to the agglomeration of macrophages and fibroblasts, the
microenvironment of a tumor also includes a large family of cell surface
receptors called integrins. Integrins consist of various combinations of
α and β subunits, each with its own binding specificity and signaling
properties. They have been shown to bind ECM components and to
regulate cytoskeleton organization, thereby exerting stringent control
on cell survival, proliferation, adhesion, and migration. Integrins are
further critical in the microenvironment of a cell because they transfer
information between cells and between cells and their surrounding
matrix. Regarding the tumor microenvironment, recent analyses have
shown that the expression of prometastatic integrins is significantly
enhanced, whereas the expression of those integrins that hinder tumor
proliferation, survival, and migration is repressed [40]. Therefore, the
types of integrins present are dependent on stimuli produced by the
microenvironment, rendering integrin expression pertinent to the under-
standing of tumor formation and progression (Figure 2).
As previously discussed, the local tumor environment is hypoxic, and
this hypoxic condition leads to the expression of the proangiogenic
factor VEGF. In relation to integrins, VEGF enhances the expression
and activation of several integrins that are pivotal to tumor angiogenesis
[41,42]. These integrins that play a leading role in new vessel formation
include the αvβ3- and α5β1-integrins. The α5β1-integrin is of particular
interest because it acts as the receptor for fibronectin (FN) during
Figure 2. The process of metastasis. The primary tumor mass secretes growth factors, cytokines, and MMPs that allow metastatic cells to
invade the circulatory system and travel to distant organs such as lungs and liver. Once they extravasate into the secondary site, the tumor
cells induce normal fibroblasts to assume a CAF phenotype. CAFs, in turn, recruit protumorigenic bone marrow–derived cells (BDMCs) to
the microenvironment, thereby supporting the growth, proliferation, and angiogenesis of the secondary tumor.
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neovascularization [43]. Current research has supported the theory that
FN dimers that are bound to the α5β1-integrin stretch and assemble
into insoluble fibrils that compose the FN matrix [44]. The fibronectin
matrix, which requires the interaction between FN and α5β1 in the
microenvironment, has become increasingly important in recruiting
fibroblasts and macrophages to the tumor area [14]. Also, keen interest
is the finding that αvβ3 integrins have been found to participate in the
formation of the FN matrix, perhaps suggesting an alternative pathway
for matrix assembly [45].
In our previous research, we have found that the protein Nischarin
interacts preferentially with the α5β1 integrin [46]. An interplay be-
tween Nischarin and α5β1 causes profound inhibition of cell migration
on fibronectin by interrupting the p21-activated kinase (PAK) pathway
[47]. Inhibiting PAK is critical in reducing cell migration because the
overexpression of PAK has been shown to increase the migration poten-
tial of epithelial cancer cells by overturning stable focal contacts at the
leading edge of the tumor mass [48]. Conversely, decreasing the levels
of endogenous Nischarin results in PAK activation and increased cell
migration [47]. Interestingly, endogenous Nischarin has been found
to be expressed in fibroblast cells. Future study may be conducted on
how altered expression of Nischarin by fibroblasts modifies cellular
dependency on the α5β1-integrin to migrate on fibronectin.
Although it has been established that αvβ3- and α5β1-integrins are
integral to matrix and therefore vessel formation, recent studies have
shown that the inhibition of eitherαvβ3- orα5β1-integrin alone has little
effect on slowing capillary tube formation. Rather, some argue that it is
the simultaneous inhibition of both the αvβ3- and α5β1-integrins that
reduces capillary tube formation by 78% [49]. Furthermore, studies
have shown that the αvβ3 integrin requires the ligation of α5β1 to inter-
nalize the matrix protein vitronectin [50]. Removing vitronectin is part
of tissue remodeling, a process necessary for tumor invasion.
Although many studies are consistent with the important role of
αvβ3- and α5β1-integrins in angiogenesis and migration, further studies
have shown that α4β1-integrins and their ligand vascular cell adhesion
molecule-1 (VCAM-1)are also crucial toproper vessel development.The
knockout of either leads to embryonic lethality in mice [51] because
the suppression of α4β1-integrin and VCAM-1 expression weakens the
normal association between endothelial and mural cells. Furthermore,
increased apoptosis and reduced angiogenesis were all observed in experi-
ments that interfered with the interaction between α4β1 and VCAM-1
[52]. This study ofα4β1 andVCAM-1 alongwith the study of the paired
function of αvβ3 and α5β1 provides support for the role of integrins in
tumor angiogenesis.
In addition to aiding tumor angiogenesis, integrins also promote cell
invasion and migration. Tumor cell migration is a key characteristic of
metastatic progression, and because migration is perhaps the most
threatening element of cancer, understanding the migrational process
is key to preventing it. Before the tumor can relocate to a secondary
site in the body, it must first break through the ECM components that
are the physical barriers for cell migration. Under normal conditions,
the basement membrane is a specialized network composed of collagen,
laminins, and proteoglycans and acts as an impermeable barrier to
malignant tumors [29]. As such, the basement membrane of the ECM
must be degraded and reorganized at the invasion front for the meta-
static tumor to migrate. However, complete degradation of the ECM
is not ideal. The tumor cells must control the extent to which the
interstitial matrix is reduced so that they can adhere to the interstitial
matrix and generate the traction necessary for migration [40]. Essen-
tially, the tumor must remodel its microenvironment, including both
the basement membrane and interstitial matrix of the ECM, to reach
the invasive stage of metastasis.
An integral part of ECM degradation is the disruption of cell-cell
adhesions in the basement membrane. When the components of the
basement membrane are lost or degraded, then tumor progression
can speed up without the barrier to migration. Integrins play a funda-
mental role in maintaining cell-matrix adhesions in the basement
membrane because they possess a transmembrane structure and have
the ability to bind to many extracellular ligands. Disrupted integrin
signaling leads to the irregular cell-cell adhesions that are hallmarks
of cancer [40]. Important in this arena are the β1-integrins, the largest
family of integrin subunits. The overexpression of β1 integrins causes
disruption of intercellular adhesions and cell scattering [53]. Conversely,
the down-regulation of β1 integrin expression and function correlates
with the reduced degradation of basement membrane-collagen in pros-
tate and breast cancer cell lines [54].
In a more precise focus than the family of β1-integrins, recent studies
have revolved around the effect of αvβ3-integrin on tumor intravasation
and extravasation. In addition to inhibiting the formation of new vessels
in angiogenesis, the αvβ3-integrin plays a functional role in the activa-
tion and expression of matrix-degrading proteases. The αvβ3-integrin
has been found to colocalize withMMP-2 at the forefront of the tumor,
corresponding to heightened collagen deterioration and subsequent
invasion [55]. For instance, blocking the interaction between αvβ3
and MMP-2 reduces the tumor progression in ovarian cancer [56].
In addition, recent studies have found that αvβ3 also colocalizes with
MT1-MMP on migrating endothelial cells, suggesting that an associa-
tion between the two plays a functional role in tumor cell migration and
invasion [57]. Thus, integrins are interdependent on the MMPs in the
microenvironment to proteolyze ECM components so that the tumor
can move through the ECM and into the circulatory system.
Beyond directly activating MMPs to degrade components of the
ECM, the αvβ3- and α5β1-integrins also work through an alternative
mechanism, mainly associating with uPAR, to recruit proteolytic activ-
ity to the leading edge of migrating cancer cells [58]. The binding of
pro-uPA to uPAR is necessary for activating uPA, which then converts
plasminogen to plasmin. Plasmin, in turn, degrades ECM components
both directly and through the activation of MMPs [59]. Thus, the
activation and expression of both β1- and αvβ3-integrins in the tumor
microenvironment contribute to the breakdown of the surrounding
ECM, significantly freeing the pathway for tumormigration and invasion.
As it pertains to the actual process of cell migration, Defilles and
Lissitsky [60] suggest that it is not one specific integrin but a complex of
αvβ5/β6- and α2β1-integrins that modulate cell migration toward type I
collagen. In two colon carcinoma cell lines, inhibition of αvβ5/β6-
integrin function lead to enhanced α2β1-integrin function through
focal adhesion rearrangements and matrix-cell signaling, as indicated
by increased levels of phosphorylated focal adhesion kinase andmitogen-
activated protein kinase (extracellular signal–regulated kinases 1 and 2).
Heightened expression of the α2β1 integrin, consequently, led to a more
than two-fold increase in integrin-dependent cell migration toward type I
collagen in colon carcinoma cells. Conversely, interfering with the α2β1-
integrin through the use of disintegrins or anti-α2 or anti-β1 monoclonal
antibodies led to significantly decreased levels of cell migration [61].
Besides theαvβ5/β6- andα2β1-integrin complex suggested byDefilles
and Lissitsky [60], the αvβ3-integrin seems to play a role in tumor cell
migration in addition to angiogenesis and ECM degradation. Integrin
αvβ3 has been shown to bind to fibroblast growth factor-1 (FGF-1),
an interaction essential to tumor cell migration [62]. In fact, FGF-1
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specifically binds to αvβ3, with only a loose association to the β1 family
of integrins. The pivotal role of αvβ3 is supported by the defective
migration ofmutant FGF-1 cells. Themutant FGF-1 cells were still able
to bind to their fibroblast growth factor receptors but unable to bind to
the αvβ3-integrin. Without the integrin interaction, the FGF-1 mutant
cells took significantly longer to migrate than those with active FGF-1/
αvβ3 associations, suggesting that direct integrin binding to FGF-1 in
the microenvironment is critical for cell migration [62].
Paracrine Signaling Pathways between the
Microenvironment and Tumor Epithelial Cells
We have discussed the abundance of different stromal cells, integrins,
endothelial, and epithelial cells in the microenvironment but not yet
the source of their recruitment, which involves a system of paracrine
signaling. The cross talk involves a number of soluble factors, such as
transforming growth factor (TGF) and various chemokines, which
act in a paracrine fashion by binding to their respective receptors. In
addition, they can work in conjunction with integrins to coordinate
cellular functions and signals.
Under normal conditions, TGF-β acts as a tumor suppressor by
inhibiting proliferation, as previous studies have shown in prostate epi-
thelial cell lines [63]. However, TGF-β has been shown to assume a
protumorigenic role as cancer progresses because those signals emitted
by CAFs modify the response of adjacent epithelial cells to other aspects
of the microenvironment [64]. For example, in a study using an ortho-
topic xenograft model to reconstruct human mammary gland, results
indicated that overexpressing TGF-β in mouse fibroblasts could induce
the initiation of breast cancer from normal epithelial tissue [65].
Several studies have indicated that TGF-β emits protumorigenic sig-
nals to surrounding cells through CXCR4/stromal cell–derived factor-1
(SDF-1) signaling pathways [63,66]. However, the exact mechanism of
CXCR4 regulation of TGF-β is not clearly understood. The expression
of TGF-β makes epithelial cells specifically sensitive to elevated levels
of SDF-1 [66]. SDF-1 is elevated in human breast cancer stroma in
which the CXCR4 pathway plays a role in tumor growth [26]. Thus,
in a feedback loop, elevated levels of TGF-β expression increase the
expression of CXCR4, which in turn causes SDF-1 to activate Akt by
phosphorylation. Phosphorylated Akt permits stroma to ignore the
growth-inhibitory effects of TGF-β, allowing for uninhibited cell prolif-
eration [66].
Also acting in a paracrine fashion with the chemokine CXCR4 is its
ligand CXCL12, which binds to CXCR4 on the membrane of cancer
cells [67]. CXCL12 promotes angiogenesis by recruiting endothelial
cells to the newly forming blood vessels. In a study that cografted
CXCR4 knockout cells with vascular endothelial cells into immuno-
deficient mice, significantly fewer blood vessels were formed [68].
CXCL12 has also been shown to trigger the invasion of transgenic
MMTV-PyMT tumors, but only through the epidermal growth factor/
colony-stimulating factor-1 paracrine loop between cancer cells and
macrophages [69]. In in vivo studies, those mice that were injected with
clodronate-containing liposomes, or those that cause macrophage deple-
tion, exhibited significantly less invasion than in the control group despite
CXCL12 expression [69]. Therefore, cross talk between tumor epithelial
cells and the microenvironment through the growth factor TGF-β or the
chemokinesCXCR4/CXCL12 seems to have amajor influence on tumor
progression and metastasis. Paracrine signaling is merely one mechanism
by which the tumor and its microenvironment interact to create a pro-
metastatic niche.
Conclusions
The microenvironmental conditions are important to the progression
of tumor metastasis. Macrophages and fibroblasts are critical to the
recruitment of prometastatic cells and to the secretion of chemokines
and growth factors, all of which the tumor mass requires for prolifera-
tion, migration, and invasion. Likewise, integrins play a role in the
activation and expression of proteases that aid in ECM degradation,
in the cell-cell adhesions that must be broken for migration to occur,
and in the formation of new blood vessels. Interestingly, the stromal
cells and integrins discussed in this article all seem to have both prome-
tastatic and antimetastatic properties and are able to “activate” one phe-
notype or the other based on the surrounding microenvironmental and
tumorigenic signals. Further study on the manipulation of these signals
has potential for therapeutic use to prevent or treat metastatic tumors.
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